Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Fluorescence assay

A 'FAIRY' to rapidly determine virus infectivity

Researchers have developed a fluorescence assay for viral integrity (or FAIRY, for short), to quickly determine the effectiveness of countermeasures against a given virus.

News • HPV oncoprotein quantification

Urine test improves cervical cancer early detection

A new test shows promise in making cervical cancer screening more accessible and less invasive by detecting oncoproteins of the human papillomavirus (HPV) in urine samples.

News • Circulating tumor extracellular vesicles

Metastatic prostate cancer: better monitoring with new liquid biopsy method

A new study shows that extracellular vesicles shed by prostate cancer cells contain tumor-derived material that can be used as biomarkers of therapy response and resistance in metastatic disease.